Unlike the brand-name prescription drug market, the nutraceuticals market is expected to grow over the coming years, and some big drugmakers are tentatively testing the waters while others are steering clear. Drugmakers are nervous about running afoul of FDA regulations, brand-name dilution and low margins, analysts say. But the market may be an excellent opportunity for pharma to refill pipelines. "Given the pipeline gap, pharma can't afford to cede the nutraceuticals market to [consumer goods companies] like Nestlé, a company that is actively climbing over the fence into pharmaceuticals," writes industry expert Ben Comer.
Published in Brief: